Industry Briefs: Apr. 30, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: Apr. 30, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

AMRI has launched Smartsourcing sourcing options for its contract manufacturing and research services. Read More

AstraZeneca and The Medicines Company have entered into a global development and commercialization pact and have agreed to copromote Brilinta (ticagrelor), for treating acute ischaemic heart disease, in the United States. Read More

Baxter International has completed its purchase of Sigma International. Read More

Cetero Research has reached a final resolution with FDA over studies the company conducted in its Houston, Texas, bioanalytical laboratory between Apr. 1, 2005 through June 15, 2010. Read More

Covance and BML are expanding the companies’ jointly owned clinical-trial laboratory in Japan. Read More

GlaxoSmithKline and the University of Nottingham are collaborating to create a Center of Excellence for sustainable chemistry. Read More

Penn Pharma has invested in additional clinical and commercial packing capabilities. Read More

Teva has settled its patent-infringement litigation with Mylan in regards to Teva’s wakefulness product Nuvigil (armodafinil). Read More

Therapure has opened a custom biologics manufacturing facility. Read More

People News

AMRI has appointed Saravanakumar Dhakshinamoorthy as director of in vitro biology. Dhakshinamoorthy will report to Takeshi Yura, senior director of AMRI’s Singapore division. Read More

Watson Pharmaceuticals has announced changes in the company’s senior leadership. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here